$0.3794
-0.0263-6.48%
Last update: Oct 23, 7:52 PM
Neumora Therapeutics Inc (NMRA) Stock Price, Quote, News & History
NMRANASDAQ
BioAge Labs stock plummeted as failed Phase 3 ZEUS trial data from Novo Nordisk sparked broad concerns for NLRP3-targeting therapies.
You can purchase shares of Neumora Therapeutics (NASDAQ:NMRA) through any online brokerage.
Other companies in Neumora Therapeutics’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).
Neumora Therapeutics has a consensus price target of $5.88.
The stock price for Neumora Therapeutics (NASDAQ: NMRA) is $0.4101 last updated October 23, 2026 at 7:52 PM EDT.
There are no upcoming dividends for Neumora Therapeutics.
Neumora Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Neumora Therapeutics.
Neumora Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic...
